Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 13/20 | 0.64 |
| ▸ | CPB1 | P15086 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3839576 | 0.97 | CPB2 (0.65) | CPB2CPB1MEN1KMT2AGAA | |
| SCHEMBL3858539 | 0.97 | CPB2 (0.65) | CPB2CPB1MEN1KMT2AGAA | |
| SCHEMBL3839173 | 0.97 | CPB2 (0.65) | CPB2CPB1MEN1KMT2AGAA | |
| SCHEMBL3841803 | 0.80 | CPB2 (0.93) | CPB2CPB1 | |
| SCHEMBL6329225 | 0.79 | CPB2 (0.64) | CPB2CPB1 | |
| Uk-396,082 SCHEMBL3839204 | 0.78 | CPB2 (1.00) | CPB2CPB1 | |
| Uk-396,082 SCHEMBL3838883 | 0.78 | CPB2 (1.00) | CPB2CPB1 | |
| Uk-396,082 SCHEMBL3841442 | 0.78 | CPB2 (1.00) | CPB2CPB1 | |
| SCHEMBL8367090 | 0.76 | CPB2 (0.74) | CPB2CPB1 | |
| SCHEMBL3889533 | 0.76 | CPB2 (0.56) | CPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311488-B1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | PFIZER LTD (GB) | 2009-11-04 | — | — | EP | disclosed |
| EP-1311488-B1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | PFIZER LTD (GB) | 2009-11-04 | — | — | EP | disclosed |
| US-6949577-B2 | Pharmaceuticals | PFIZER, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030236420-A1 | Pharmaceuticals | ALLERTON CHARLOTTE MOIRA NORFO (GB) | 2003-12-25 | — | — | US | disclosed |
| US-20020147229-A1 | Pharmaceuticals | PFIZER INC. | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147229-A1 | Pharmaceuticals | BDKRB1, TFPI, BDKRB2 | CPB2 234/4885CPB1 168/4885MEN1 575/4885 |
| US-20030236420-A1 | Pharmaceuticals | BDKRB1, TFPI, SERPINE1 | CPB2 167/4885CPB1 181/4885MEN1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.